ArticleJNCI cancer spectrum2026
Genetic risk stratification of common diseases in breast cancer survivors: a population-based cohort study.
Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients diagnosed with breast cancer are at increased risk of multiple common diseases; however, the spectrum of these diseases and the contribution of inherited genetic susceptibility remain incompletely characterized.
methodsWe evaluated 15 common diseases and tested their associations with breast cancer exposure and disease-specific polygenic risk scores in the UK Biobank (n = 254 736). Analyses were performed using cause-specific Cox proportional hazards models within a full-cohort framework, with time-updated breast cancer status, delayed entry at study recruitment, and age as the underlying time scale.
resultsAfter recruitment, incident breast cancer was diagnosed in 11 386 women (4.47%), including 2742 (24.08%) with metastatic breast cancer. Patients with breast cancer had an increased risk of 9 diseases spanning cardiovascular, metabolic, and neuropsychiatric domains (P < .003, Bonferroni corrected). Elevated risks were generally observed among patients with both early-stage and advanced breast cancer. Inherited susceptibility further stratified disease risk, with the highest risks observed among patients with breast cancer and elevated disease-specific polygenic risk scores. For example, compared with women without breast cancer, the hazard ratio for osteoporosis was 2.33 (95% CI = 2.15 to 2.52) among women with any breast cancer, 2.38 (95% CI = 2.18 to 2.59) among women with nonmetastatic breast cancer, and 2.12 (95% CI = 1.78 to 2.54) among women with metastatic breast cancer; the hazard ratio was 4.48 (95% CI = 3.99 to 5.02) among patients with breast cancer in the highest quartile of osteoporosis-specific polygenic risk scores (all P < .001). In contrast, breast cancer was not statistically significantly associated with risk of coronary artery disease.
conclusionBreast cancer and inherited genetic susceptibility jointly contribute to increased risk of multiple common diseases, supporting the integration of genetic risk stratification into survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.